AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32789625 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to take PrEP
Number of subjects: 0
Study 32789625 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived efficacy of daily HIV pill
Number of subjects: 0
Study 35315344 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 77
Study 34323977 — intervention group
Group type: EXPERIMENTAL
Intervention: M2-deficient single replication (M2SR) vaccine
Number of subjects: 0
Study 34323977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34511295 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol box
Number of subjects: 28
Study 34511295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation tent
Number of subjects: 28
Study 34511295 — intervention group
Group type: COMPARATOR
Intervention: No device use
Number of subjects: 28
Study 34527408 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/kg fentanyl (group 2)
Number of subjects: 60
Study 34527408 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (group 1)
Number of subjects: 60
Study 34527408 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone + 1 μg/kg fentanyl (group 3)
Number of subjects: 60
Study 33008345 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR), starting dose 2 mg/day, maintenance dose 4-6 mg/day for 50 weeks
Number of subjects: 191
Study 36347555 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde filling (RF) method
Number of subjects: 56
Study 36347555 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous voiding (SV) method
Number of subjects: 56
Study 35703355 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 527
Study 34976049 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralaterally Controlled Functional Electrical Stimulation (CCFES)
Number of subjects: 50
Study 34976049 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 50
Study 35797794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 20
Study 32989579 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative low molecular weight heparin (LMWH) prophylaxis alone starting from day 1 to day 15 at a dose of 1 mg/kg/day (maximum 120 mg/day)
Number of subjects: 100
Study 32989579 — intervention group
Group type: COMPARATOR
Intervention: Both pre‐ and postoperative LMWH starting from 12 hours preoperatively and continuing from day 1 to day 15 at the same dose
Number of subjects: 100
Study 32989579 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative low molecular weight heparin (LMWH) prophylaxis alone
Number of subjects: 100
Study 32989579 — intervention group
Group type: COMPARATOR
Intervention: Both pre‐ and postoperative LMWH
Number of subjects: 100
Study 33687052 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-supplemented lipofilling with mechanically isolated SVF
Number of subjects: 28
Study 33687052 — intervention group
Group type: COMPARATOR
Intervention: PRP-supplemented lipofilling
Number of subjects: 28
Study 33340279 — intervention group
Group type: EXPERIMENTAL
Intervention: PC945 (5 mg single inhalation)
Number of subjects: 0
Study 33340279 — intervention group
Group type: EXPERIMENTAL
Intervention: PC945 (5 mg daily for 7 days)
Number of subjects: 0
Study 33340279 — intervention group
Group type: EXPERIMENTAL
Intervention: PC945 (0.5-10 mg single inhalation)
Number of subjects: 0
Study 33340279 — intervention group
Group type: EXPERIMENTAL
Intervention: PC945 (daily 2-hour inhalation for 14 days)
Number of subjects: 0
Study 33340279 — intervention group
Group type: EXPERIMENTAL
Intervention: PC945
Number of subjects: 0
Study 32019696 — intervention group
Group type: EXPERIMENTAL
Intervention: High humility physician
Number of subjects: 417
Study 32019696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low humility physician (ineffective)
Number of subjects: 417
Study 32019696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low humility physician (family practice)
Number of subjects: 417
Study 35805787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group)
Number of subjects: 0
Study 35805787 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study 35805787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group) with IL-6 SNP
Number of subjects: 0
Study 35805787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group) with GG IL-6 genotype
Number of subjects: 0
Study 35805787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group) with HSPA1A genotypes
Number of subjects: 0
Study 34191185 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent need for paracentesis
Number of subjects: 942
Study 34191185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin (per 10 µmol/l increase)
Number of subjects: 942
Study 34191185 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 942
Study 34191185 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-use of non-selective beta-blockers (NSBBs)
Number of subjects: 942
Study 34191185 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of hepatic hydrothorax
Number of subjects: 942
Study 32091953 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic deep brain stimulation (DBS) of the caudal zona incerta (cZi)
Number of subjects: 35
Study 32091953 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral stimulation at increasing amplitude levels
Number of subjects: 35
Study 32091953 — intervention group
Group type: COMPARATOR
Intervention: Bilateral and unilateral treatments
Number of subjects: 35
Study 35074399 — intervention group
Group type: EXPERIMENTAL
Intervention: RX: xylazine (0.2 mg/kg)
Number of subjects: 6
Study 35074399 — intervention group
Group type: EXPERIMENTAL
Intervention: RXD1: xylazine (0.2 mg/kg) and doxapram (0.1 mg/kg)
Number of subjects: 6
Study 35074399 — intervention group
Group type: EXPERIMENTAL
Intervention: RXD2: xylazine (0.2 mg/kg) and doxapram (0.2 mg/kg)
Number of subjects: 6
Study 35074399 — intervention group
Group type: COMPARATOR
Intervention: RS: saline
Number of subjects: 6
Study 33330899 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) 302 mg
Number of subjects: 0
Study 33330899 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) 604 mg
Number of subjects: 0
Study 33330899 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) 906 mg
Number of subjects: 0
Study 33330899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33824973 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing by a trained nurse practitioner (3 visits of 15 minutes each over 3 months)
Number of subjects: 136
Study 33824973 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation by a nurse practitioner (after 1 and 3 months)
Number of subjects: 136
Study 32271041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical linear models (HLM)
Number of subjects: 0
Study 32271041 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression with two‐way cluster adjusted standard errors
Number of subjects: 0
Study 36247104 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (2 ml) plus dexmedetomidine 1 μg/kg diluted in 1 ml saline 0.9% (0.5 ml in each tonsil)
Number of subjects: 90
Study 36247104 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.25% (2 ml + 0.5 ml saline 0.9% per tonsil)
Number of subjects: 90
Study 33814447 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone and rosiglitazone XR
Number of subjects: 360
Study 33814447 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 360
Study 616118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185
Study 616118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185
Study 616118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal fluid (SRF) present
Number of subjects: 1185
Study 616118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraretinal fluid (IRF) present
Number of subjects: 1185
Study 616118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal thickness <120 microns
Number of subjects: 1185
Study 616118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater subretinal tissue complex thickness
Number of subjects: 1185
Study 616118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater CNV lesion area
Number of subjects: 1185
Study 32985265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive balance and gait training (10 weeks, 3 times/week)
Number of subjects: 100
Study 32074365 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (PTSD Clinicians Exchange)
Number of subjects: 605
Study 34524370 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program (G1)
Number of subjects: 36
Study 34524370 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic and aerobic exercise program (G2)
Number of subjects: 36
Study 34524370 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise program (G3)
Number of subjects: 36
Study 36361237 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-Free Anaesthesia (OFA) combined with a paravertebral block with 0.5% bupivacaine
Number of subjects: 50
Study 36361237 — intervention group
Group type: COMPARATOR
Intervention: Typical general anaesthesia with opioids (Control)
Number of subjects: 50
Study 36361237 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-Free Anaesthesia (OFA)
Number of subjects: 50
Study 33648866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute IPC (3 × 5 min at 220 mmHg)
Number of subjects: 23
Study 33648866 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated IPC (3 days x 3 × 5 min at 220 mmHg)
Number of subjects: 23
Study 33648866 — intervention group
Group type: COMPARATOR
Intervention: SHAM (3 × 5 min at 20 mmHg)
Number of subjects: 23
Study 32943079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention
Number of subjects: 200
Study 32943079 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study 34911711 — intervention group
Group type: COMPARATOR
Intervention: Patient Training Intervention (PTI)
Number of subjects: 2334
Study 34911711 — intervention group
Group type: COMPARATOR
Intervention: Professional Training Intervention (PFI)
Number of subjects: 2334
Study 34911711 — intervention group
Group type: COMPARATOR
Intervention: Combined Intervention (CBI)
Number of subjects: 2334
Study 34911711 — intervention group
Group type: COMPARATOR
Intervention: PTI and CBI (smoking cessation)
Number of subjects: 2334
Study 32897809 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive mothers
Number of subjects: 297
Study 32897809 — intervention group
Group type: COMPARATOR
Intervention: Unsupportive mothers
Number of subjects: 297
Study 34309927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) at the trapezius muscle
Number of subjects: 2198
Study 34309927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) at the tibialis muscle
Number of subjects: 2198
Study 34309927 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning pain modulation (CPM)
Number of subjects: 2198
Study 33044703 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Assurance (QA) practices
Number of subjects: 23
Study 33044703 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Control (QC) practices
Number of subjects: 23
Study 616541541 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended monitoring with entropy
Number of subjects: 74
Study 616541541 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 74
Study 35573842 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion group (2 mL/h infusion, 10-min lockout time)
Number of subjects: 60
Study 35573842 — intervention group
Group type: COMPARATOR
Intervention: No background infusion group (6-min lockout time)
Number of subjects: 60
Study 35573842 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion group
Number of subjects: 60
Study 35573842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 33184076 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 180
Study 33184076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35684144 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-enriched oral nutritional supplement (1.5 g of calcium HMB per bottle, twice a day for 12 weeks)
Number of subjects: 43
Study 35684144 — intervention group
Group type: COMPARATOR
Intervention: HMB-free oral nutritional supplement (similar composition devoid of HMB, twice a day for 12 weeks)
Number of subjects: 43
Study 34404678 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed external chest compression (ECC)
Number of subjects: 0
Study 34404678 — intervention group
Group type: COMPARATOR
Intervention: One-handed external chest compression (ECC)
Number of subjects: 0
Study 32869577 — intervention group
Group type: EXPERIMENTAL
Intervention: Along-meridian trochar acupuncture therapy, 3 times a week for 3 weeks.
Number of subjects: 80
Study 32869577 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture therapy with filiform needles, 5 times a week for 3 weeks.
Number of subjects: 80
Study 35048993 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPE cup
Number of subjects: 48
Study 35048993 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE cup
Number of subjects: 48
Study 33160719 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.05 or 0.1 mg/kg)
Number of subjects: 30
Study 33160719 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg intravenously)
Number of subjects: 30
Study 32887521 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-week savoring positive intervention via Facebook
Number of subjects: 61
Study 32887521 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 61
Study 36214599 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG cookstove and fuel (intervention group)
Number of subjects: 3200
Study 36214599 — intervention group
Group type: COMPARATOR
Intervention: Biomass cookstove (control group)
Number of subjects: 3200
Study 33914154 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 25
Study 33914154 — intervention group
Group type: COMPARATOR
Intervention: ET
Number of subjects: 25
Study 34776145 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release with portable electric massager at 25 Hz
Number of subjects: 14
Study 34776145 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release with portable electric massager at 52 Hz
Number of subjects: 14
Study 34776145 — intervention group
Group type: COMPARATOR
Intervention: Myofascial release with portable electric massager (both frequencies)
Number of subjects: 14
Study 34776145 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release with portable electric massager (deep layer at knee flexed 45°)
Number of subjects: 14
Study 34776145 — intervention group
Group type: COMPARATOR
Intervention: Myofascial release with portable electric massager (both layers at knee extended 0°)
Number of subjects: 14
Study 32185692 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP) in obese patients
Number of subjects: 219
Study 32185692 — intervention group
Group type: COMPARATOR
Intervention: Controlled Attenuation Parameter (CAP) in non-obese patients
Number of subjects: 219
Study 32185692 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM) in obese patients
Number of subjects: 219
Study 32185692 — intervention group
Group type: COMPARATOR
Intervention: Liver stiffness measurement (LSM) in non-obese patients
Number of subjects: 219
Study 32185692 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CAP cut-off values for steatosis in non-obese patients
Number of subjects: 219
Study 32185692 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CAP cut-off values for steatosis in obese patients
Number of subjects: 219
Study 32185692 — intervention group
Group type: COMPARATOR
Intervention: Discordance between CAP and biopsy measured steatosis in non-obese NAFLD
Number of subjects: 219
Study 32185692 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance between CAP and biopsy measured steatosis in obese NAFLD
Number of subjects: 219
Study 32185692 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP performance in predicting steatosis
Number of subjects: 219
Study 35345661 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (Buqi Huoxue Decoction + cardiac rehabilitation care)
Number of subjects: 120
Study 35345661 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group
Number of subjects: 120
Study 35345661 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional antiplatelet therapy)
Number of subjects: 120
Study 35345661 — intervention group
Group type: COMPARATOR
Intervention: Cardiac care group
Number of subjects: 120
Study 35345661 — intervention group
Group type: COMPARATOR
Intervention: TCM + WM group (Buqi Huoxue Decoction + conventional treatment)
Number of subjects: 120
Study 35345661 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 33975094 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine patch
Number of subjects: 72
Study 33975094 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 72
Study 36106759 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-labeled placebo (OLP) administered as one tablet twice a day for 7 days, followed by 3 weeks of placebo for all patients.
Number of subjects: 84
Study 36106759 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL) for 7 days, followed by 3 weeks of placebo for all patients.
Number of subjects: 84
Study 36106759 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-labeled placebo (OLP) after day 8 for all patients.
Number of subjects: 84
Study 36106759 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-labeled placebo (OLP) on day 8.
Number of subjects: 84
Study 34130676 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based serious gaming (VRBSG)
Number of subjects: 50
Study 34130676 — intervention group
Group type: COMPARATOR
Intervention: Lecture instruction
Number of subjects: 50
Study 32650688 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adjudication of outcomes in stroke trials
Number of subjects: 25436
Study 35459970 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological determinist condition
Number of subjects: 183
Study 35459970 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic condition
Number of subjects: 183
Study 35459970 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 183
Study 32141014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegadermâ„¢
Number of subjects: 0
Study 32141014 — intervention group
Group type: COMPARATOR
Intervention: EyeGardÂ®
Number of subjects: 0
Study 36450129 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir-eluting implant (48 mg, 52 mg, or 56 mg)
Number of subjects: 36
Study 36450129 — intervention group
Group type: COMPARATOR
Intervention: Placebo implant
Number of subjects: 36
Study 33331040 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel dental gel containing 2.6% EDTA
Number of subjects: 65
Study 33331040 — intervention group
Group type: COMPARATOR
Intervention: Commercially available anti-gingivitis dentifrice with 0.454% stannous fluoride
Number of subjects: 65
Study 34203155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Brief salt reduction instruction by a physician
Number of subjects: 0
Study 34203155 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Notification of current salt intake only
Number of subjects: 0
Study 32430458 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 units/mL (Gla-300)
Number of subjects: 463
Study 32430458 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine 100 units/mL (Gla-100)
Number of subjects: 463
Study 34181880 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (0.3 mL) via a single intramuscular injection
Number of subjects: 676
Study 34181880 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 676
Study 32388273 — intervention group
Group type: EXPERIMENTAL
Intervention: PM10
Number of subjects: 218
Study 32388273 — intervention group
Group type: EXPERIMENTAL
Intervention: O3
Number of subjects: 218
Study 32388273 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5
Number of subjects: 218
Study 32388273 — intervention group
Group type: EXPERIMENTAL
Intervention: PM10 and O3
Number of subjects: 218
Study 34796757 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial customization with DBDM (IC + DBDM)
Number of subjects: 88
Study 34796757 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial customization of the intervention (IC-only)
Number of subjects: 88
Study 34796757 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual comparison condition
Number of subjects: 88
Study 33761920 — intervention group
Group type: EXPERIMENTAL
Intervention: FTT + HPV intervention group
Number of subjects: 519
Study 33761920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 519
Study 36185306 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nurse monitoring phone call and educational leaflet
Number of subjects: 0
Study 36185306 — intervention group
Group type: COMPARATOR
Intervention: Educational leaflet only
Number of subjects: 0
Study 33428177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovateltide (0.3 µg/kg, intravenous bolus over 1 min, three doses on day 1, day 3, and day 6)
Number of subjects: 40
Study 33428177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovateltide
Number of subjects: 40
Study 33428177 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study 36253717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + propofol (Group L)
Number of subjects: 59